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Abstract 
IL-17-producing CD4+ T cells (Th17 cells) are understood to be a distinct lineage of CD4+ T helper (Th) cells, 
which play an important role in the host defense, tissue inflammation and autoimmunity. The identification of 
Th17 cells collapsed the concept of the previously held Th1/Th2 paradigm in infection and autoimmunity. 
Recent studies have provided new information on the role of Th17 cells in different autoimmune diseases and the 
mechanisms of Th17 cell differentiation. Th17 cells contribute to the exacerbation of autoimmune disease, 
whereas they possess a protective aspect against microbes such as bacteria and fungi. This suggests that Th17 
cells can be broadly categorized as pathogenic or non-pathogenic. Naïve CD4+ T cells can differentiate into 
Th17 cells in synergy with IL-6 and TGF-β, while TGF-β induces regulatory T cells (iTreg), which appear to be 
mutually exclusive to Th17 cells. Here we describe the detail molecular mechanism of Th17 cell differentiation, 
including recently identified molecules, and discuss different roles of Th17 cells in infection, inflammation and 
autoimmunity in a cytokine milieu. 
 
1- Introduction 
CD4+ T cells play a pivotal role in host defense, but 
are also recognized to have pathogenic roles such as 
in autoimmunity, asthma, cancer and allergic 
responses (Zhu et al., 2010).  
On activation by co-stimulatory molecules and 
particular cytokines, naïve CD4+ T cells can 
differentiate into the distinct lineage of T helper 
(Th) cells with different immunological functions, 
including Th1, Th2, Th17 cells, and regulatory T 
cells (Treg).  
Th1 cell polarization was driven by IL-12 and IFN-
γ, and Th1 cells, which produced IFN-γ, elicited 
cell-mediated immunity against intracellular 
pathogen, whereas Th2 cells, which secreted IL-4, 
IL-5, and IL-13 (Abbas et al., 1996), were induced 
by IL-4, and involved in immune responses against 
extracellular parasites such as helminthes and 
nematodes (Pearce et al., 2002).  
Th1 and Th2 cells were shown to be mutually 
exclusive (Hwang et al., 2005). In Th1 cells, IL-12 
activated Stat4 and induced IFN production, which 
led to the expression of master transcription factor 
T-box (Tbx21, T-bet).  
In Th2 cells, IL-4 enhanced Stat6 signaling, which 
upregulated the transcriptional factor GATA3.  
T-bet inhibited Th2 differentiation by attenuating 
the function of GATA3, whereas GATA3 
contributed to the repression of Th1 cell lineage.  
More recently, IL-17-producing T (Th17) cells, as a 
third of T cell lineages, have been identified 
(Harrington et al., 2005; Park et al., 2005). 
Although it was initially demonstrated that IL-23 
drives Th17 cell polarization via Stat3 activation in 
the absence of IFN-γ, it was generally assumed that 
the effect of IL-23 was limited in effector and 
memory CD4+ T cells (Oppmann et al., 2000; 
Aggarwal et al., 2003; Langrish et al., 2005). 
Subsequently, the synergy between TGF-β and IL-6 
has been shown to efficiently induce the 
development of Th17 cells through Smad and Stat3 
pathway, respectively (Bettelli et al., 2006; 
Veldhoen et al., 2006). In contrast, TGF-β alone 
converted naïve CD4+CD25- T cells into 
CD4+CD25+ regulatory T cells (Chen et al., 2003).  
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The immunopathogenesis of infection, 
autoimmunity, and allergy has been extensively 
attributed to the concept of Th1/Th2 paradigm. 
However, it has been recently reported that CIA and 
EAE are exacerbated rather than improved under 
inhibition of Th1 cell-inducing condition such as 
deficiency of IFN-γR, IL-12 p35 or Stat1 (Iwakura 
and Ishigame, 2006). Cua et al. has demonstrated 
that IL-23 rather than IL-12 influences the critical 
pathogenic effect on autoimmunity such as EAE. 
Subsequently, by the same group, it has been shown 
that IL-23 promotes the development and expansion 
of effector CD4+ T cells, which highly produce IL-
17, and IL-17 secreted from activated CD4+ T cells 
play an important role in various autoimmune 
diseases (Langrich et al., 2005).  
The balance between Th17 and Treg cells is an 
important factor involved in the pathogenesis of 
autoimmunity. Sakaguchi et al. initially 
demonstrated that a population of CD4+CD25+ T 
cells derived from the thymus, known as nTreg, 
exhibited the inhibitory effect in immunity. TGF-β1 
is required for the differentiation of both Treg and 
Th17 cells, whereas IL-6 suppresses Treg cell 
population and drives the development of Th17 
cells. This suggests a dichotomy between these 
cells (Bettelli et al., 2007). However, it still remains 
to be understood how IL-6 in combination with 
TGF-β drives Th17 cell differentiation, and which 
cytokine milieu makes Th17 cells "pathogenic" in 
vivo. In this review, we discuss the mechanism of 
Th17 cell differentiation, its plasticity and 
pathogenicity in immune regulation, and its link 
with inflammatory disease and autoimmunity. 
2- Regulation of Th17 polarization  
The mechanism of Th17 differentiation has been 
extensively studied with respect to the 
transcriptional regulation. Betteli et al. found that 
IL-6 but not IL-23 was a potent inducer for Th17 
cell differentiation in combination with TGF-β1. It 
was initially shown that retinoic acid (RA)-related 
orphan receptor γ thymus (Rorγt) was an essential 
transcriptional factor for identifying a distinct 
lineage of CD4+ T cells (Th17 cells), which 
constitutively produced IL-17 in the lamina propria 
of the small intestine (Ivanov et al., 2006). 
IL-6 signaling 
IL-6 mainly activates Stat3 via the Jak-Stat 
pathway (Kishimoto, 2005). The role of Stat3 in 
Th17 cell differentiation was extensively analyzed 
by chromatin immunoprecipitation and massive 
parallel sequencing (ChIP-Seq), in which STAT3 
bound to the promoter of cytokine and 
transcriptional genes including the Rorc, IL-17, IL-
17F, Ahr and IL-21 genes. Possibly Stat3 also 
interacted with the BATF, IRF4, and c-Maf genes 
(Durant et al., 2010). These transcriptional factors 
played an important role in Th17 cell differentiation 
(Ciofani et al., 2012; Yosef et al., 2013). 
BATF, which is a basic leucine zipper (b-Zip) 
transcription factor of the AP-1 protein family, 
contributed to the generation of Th17 cells 
(Schraml et al., 2009). It has recently been reported 
that BATF is a multifunctional transcriptional 
factor, in which BATF is also required for the 
generation of T follicular helper (Tfh) cells but not 
Th1 cells and Treg cells (Betz et al., 2010; Ise et al., 
2011). More recently, BATF in cooperation with 
IRF-4, which is also essential for the development 
of both Th2 and Th17 cells (Brüstle et al., 2009), 
has been shown to be involved in the induction of 
the IL10, IL-17a, and IL-21 genes in T cells 
(Glasmacher et al., 2012; Li et al., 2012; Tussiwand 
et al., 2012; Murphy et al., 2013). Although it is 
still not clear whether the BATF gene is directly 
regulated by Stat3 activation, recent studies have 
shown that IL-6 activates the function of 
BATF/IRF4 complex (Koch et al., 2013).  
More recently, our group has also identified a key 
molecule, AT-rich interactive domain 5a (Arid5a), 
which is induced under Th17 cell-polarizing 
condition. Arid5a deficiency inhibits the 
differentiation of Th17 cells (unpublished data). 
Our previous report has shown that Arid5a 
positively controls IL-6 mRNA through its 3'-
untranslated region (UTR). IL-6 serum level in 
Arid5a deficient mice was dramatically reduced 
after LPS injection compared to WT mice, and EAE 
was also ameliorated, in which the frequency of 
Th17 cell population was inhibited, whereas that of 
Th1 cells was enhanced, but not Treg cells (Masuda 
et al., 2013). 
IL-21 and IL-23 signaling 
IL-21 or IL-23 as well as IL-6 enhanced Stat3 
activation in Th17 cells via IL-21R or IL-23R 
(Muranski et al., 2013). IL-21 has been shown to 
have pleiotropic effects on T cells and B cells 
(Leonard et al., 2005). IL-21 independent of IL-6 
was able to drive naïve T cells into Th17 cells in 
the presence of TGF-β1 (Chen et al., 2007). 
Nonetheless, IL-6 activates IL-21 expression in 
naïve CD4+ T cells via Stat3 activation and IL-21 
production is amplified under Th17 cell-inducing 
condition through an autocrine-loop (Zhou et al., 
2007; Nurieva et al., 2007).  
IL-23 is a heterodimeric cytokine composed of p19 
and p40 subunits. IL-23 binds to IL-23R composed 
of IL-12Rβ1 and IL23R subunits (Parham et al., 
2002), and mainly activates Stat3 through the Jak-
stat pathway (Cesare et al., 2009). It was initially 
reported that IL-23 contributed to the proliferation 
of effector CD4+ T cells (Oppmann et al., 2000). 
Subsequently, Parham et al. found that naïve CD4+ 
T cells did not respond to IL-23, and express little 
or no IL-23R.  
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Figure 1. Pathogenic Th17 cells were induced by different patterns of cytokines or a chemical, and displayed a unique 
character in the expression of possible master regulators and chemokine receptors, respectively. Naïve CD4+ T cells 
differentiate into Th17 cells, which mainly express Rorγt, in the presence of IL-6 and TGF-β1. The Th17 cells primarily produce 
IL-17, and secret IL-10. IL-23 drives the expansion and proliferation of Th17 cells, and activated Th17 cells secret IL-17, IL-22, 
and GM-CSF as well as TGF-β3, whereas the production of IL-10 is inhibited in such a pathogenic Th17 cells. A recent study 
has shown that sodium chloride is a strong enhancer of Th17 cells. The high salt-induced Th17 cells display highly pathogenic, 
and produce GM-CSF, TNF-α, and IL-2 as well as IL-9. Moreover, it has been reported that there is a direct pathway for the 
generation of pathogenic Th17 cells in the presence of IL-6 and TGF-β3. In the Th17 cells, the expression of GM-CSF, IL-23R, 
and Tbx21 is highly upregulated, while IL-10 expression is critically attenuated. These pathogenic Th17 cells commonly express 
Rorγt, T-bet, and IL-23 R. The Th17 cells under high-salt conditions express serum glucocorticoid kinase 1 (SGK1) downstream 
of IL-23R signaling, which critically contributes to the induction of pathogenic Th17 cells. Activated Th17 cells also express some 
chemokine receptors, including CCR4, CCR6 and CCR10. However, it still remains to be elucidated what kinds of key molecules 
could become master regulators in such a pathogenic Th17 cells. 
 
 
Rather, IL-23R was induced in the process of Th17 
polarization, and Th17 cell differentiation was 
promoted by IL-23 (Betteli et al., 2006; Mangan et 
al., 2006; Veldhoen et al., 2006). Of note, IL-23 is 
one of the most important cytokines, which convert 
the Th17 cells differentiated from naïve CD4+ T 
cells exposed to IL-6 and TGF-β1 into the 
"pathogenic" Th17 (Figure 1). It has been 
confirmed that Th17 cells induced by IL-6 and 
TGF-β in the absence of IL-23 are not sufficient to 
induce EAE (McGeachy et al., 2007), in which IL-
23 diminished the expression of IL-10 produced 
from such "non-pathogenic" Th17 cells. This result 
suggests that IL-10 is a key molecule, which 
distinguishes pathogenic Th17 from non-pathogenic 
types (Figure 2). Consistent with this, Lee et al. and 
Kleinewietfeld et al. have demonstrated that IL-10 
expression in pathogenic Th17 is suppressed 
compared to non-pathogenic ones. Furthermore, IL-
23 upregulated the Tbx-21 gene (encode T-bet) in 
pathogenic Th17 (Lee et al., 2012; Yang et al., 
2009; Kleinewietfeld et al., 2013). However, it 
must be further investigated which molecules are 
critical for the generation and stability of 
pathogenic Th17 under IL-23 signaling or other 
pathways (Figure 1). 
TGF-β signaling 
Transforming growth factor β (TGF-β) has complex 
roles in cell growth and development (O'Kane and 
Ferguson, 1997). TGF-β as well as IL-10 negatively 
regulates immune responses including autoimmune 
disease and inflammation (Letterio and Roberts, 
1998; Moore et al., 2001). It is currently understood 
that there are at least three mammalian TGF-β 
isoforms (TGF-β1, 2, and 3). TGF-β is an essential 
factor for the generation of CD4+ CD25+ regulatory 
T cells (iTreg), which express the forkhead/winged 
helix transcription factor Foxp3 (Chen et al., 2003; 
Batteli et al., 2006; Hori et al., 2003). Notably, IL-2 
is required for the generation of iTreg (Zheng SG et 
al., 2007), whereas IL-2 signaling via Stat5 inhibits 
the differentiation of Th17 cells in vivo and in vitro 
by ameliorating IL-6 signaling pathway (Liao et al., 
2011; Chen et al., 2011; Laurence et al., 2007).  
The TGF-β superfamily activates not only Smad-
dependent but also Smad-independent pathways 
(Derynck and Zhang, 2003). TGFβ1 and TGFβ3 
bind type II receptors on T cells, which leads to the 
activation of Smad1, 2, 3 and 5, although Smad2 
and Smad3 are activated in a different way from the 
activation of Smad1 and Smad5 (Derynck and 
Zhang, 2003). As mentioned above, TGFβ1 
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induced the differentiation of Th17 cells in the 
presence of IL-6, although the Th17 cells did not 
show the pathogenicity in autoimmunity possibly 
due to the elevation of IL-10 production 
(McGeachy et al., 2007). Of note, c-Maf, which is 
induced by TGF-β signaling (Rutz et al., 2011), 
contributes to the generation of "non-pathogenic" 
Th17 cells, in which the expressions of Rora, 
Runx1, IL-1R1, Ccl6 and TNF-α are suppressed, 
whereas the expressions of IL-10, IL-9, Lif and 
CTLA-4 are enhanced (Ciofani et al., 2012; Xu et 
al., 2009), although it initially has been reported 
that c-Maf is required for the differentiation of 
Th17 cells (Bauquet, 2009, Nat.Immunol.). Such 
recent data may shed light on the question of how 
Th17 cells switches from pathogenic into non-
pathogenic and vice versa in infection and 
autoimmunity (Figure 1), because non-pathogenic 
Th17 cells produce more IL-10 than pathogenic 
Th17 cells (McGeachy et al., 2007; Lee et al., 
2012).  
In contrast, Lee et al. have recently shown that 
TGF-β3 directly drives naïve CD4+ T cells into 
"pathogenic" Th17 cell in the presence of IL-6 (Lee 
et al., 2012). In this report, TGF-β3-induced Th17 
cells highly expressed T-bet and IL-23R, and the 
expression of IL-10 was suppressed compared with 
those of TGF-β1-induced Th17 cells (Figure 1). 
TGF-β activated Smad1 and Smad5 rather than 
Smad2 and Smad3. These results suggest that 
Smad1 and Smad5 pathway might be important for 
the generation of pathogenic Th17 but not non-
pathogenic cells. Further investigation of the 
molecular mechanism of TGF-β3 signaling is able 
to lead to immunotherapy specifically targeting 
pathogenic Th17 cells.  
As mentioned above, IL-2 is a potent suppressor of 
Th17 cell generation. TGF-β1 inhibited IL-2 
mediated Stat5 signaling (Bright et al., 1997), and 
also attenuated the expression of T-bet and 
GATA3, which resulted in elimination of Th1 or 
Th2 differentiation (Carsten et al., 2007). It has 
been also reported that TGF-β1 produced from 
CD4+ effector T cells, including Th17 cells, is 
essential for the differentiation and stabilization of 
Th17 cells (Gutcher et al., 2011). Thus, it seems 
that TGF-β1 is essential for initial Th17 
polarization in vitro and in vivo. In contrast, it has 
been reported that TGF-β signaling is not necessary 
for the generation of pathogenic Th17 cells. Rather, 
TGF-β1 inhibited the generation of pathogenic 
Th17 cells (Ghoreschi et al., 2010). 
Aryl hydrocarbon receptor (Ahr) signaling and 
other signaling pathways 
Aryl hydrocarbon receptor (Ahr) is a key factor for 
the development of Th17 and Th22 cells. Ahr, 
which normally resides in the cytoplasm, is a 
ligand-activated transcriptional factor. On 
recognizing products of tryptophan metabolism as 
natural ligands or toxic dioxins such as TCDD, Ahr 
functions as a transcriptional factor. Our group and 
two other groups found that Ahr is induced under 
Th17 cell polarizing condition, and involved in 
autoimmunity including EAE and CIA (Kimura et 
al., 2008; Veldhoen et al., 2008; Quintanna et al., 
2008; Nakahama et al., 2011). Recently, our group 
also has shown the role of miR132/212 cluster 
induced by Ahr in the differentiation of Th17 cells 
(Nakahama et al., 2013). Although it still remains 
to be understood how Ahr drives Th17 cell 
polarization in vivo, we have recently detailed role 
of Ahr in immune responses, including the possible 
mechanism of Ahr for Th17 cell differentiation 
(Nguyen et al., 2013). This was a unique 
demonstration linking environment and 
autoimmunity. Recently, as an environmental factor 
involved in autoimmunity, it has been reported that 
high salt diet might lead to autoimmunity, in which 
sodium chloride accelerates EAE through induction 
of Th17 cells (Kleinewietfeld et al., 2013).  
Retinoic acid (RA), a vitamin A metabolite, has 
been shown to mediate reciprocal Th17 and Treg 
cell differentiation (Mucida et al., 2007). RA with 
TGF-β contributed to stabilization of Treg cells, 
and negatively regulates Th17 cell differentiation 
(Takahashi et al., 2012). In contrast, RA promoted 
effector T cells via retinoic acid receptor α (Rora) 
in vivo. Thus, RA controls a dichotomy between 
Treg and Th17 cells in a concentration-dependent 
manner.  
The mammalian target of rapamycin (mTOR) 
signaling is involved in the maintenance and 
proliferation of Th17 cells (Chi et al., 2012). mTOR 
signaling is activated by TCR and/or IL-1β 
stimulation via Myd88 (Powell et al., 2012; Chang 
et al., 2013), in which IRF4 expression was 
regulated (Yao et al., 2013). As mentioned above, 
the complex of BATF and IRF4 is essential for the 
generation of Th17 cells. BATF is rapidly induced 
by TCR stimulation, and then BATF and IRF4 
plays a synergistic role in setting the initial 
transcriptional program, including chromatin 
remodeling and cooperation in accessibility of the 
transcriptional factors to target genes such as the 
IL-17 gene (Ciofani et al., 2012).  
IL-27 (a member of the IL-12 family of cytokines) 
signaling contributes to inhibition of Th17 
differentiation (Pot et al., 2011). IL-27 binds to a 
receptor complex composed of WSX1 (IL-27R) and 
gp130, and in turn activates both Stat1 and Stat3. 
IL-27 also induces IL-10 expression in CD4+ T 
cells, whereas IL-27 inhibits IL-17, IL-22, and GM-
CSF expression through suppression of Rorγt 
activation. Thus, IL-27 is a potent negative 
regulator of Th17 cell polarization.  
Taken together, a large number of transcriptional 
factors control Th17 cell differentiation, in which a 
balance between the activation of Stat3 and other 
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Stat families (Stat1, 4, 5, and 6) may be an 
important factor for driving Th17 cell 
differentiation. Moreover, it is for future studies to 
decipher the molecular circuits and regulatory 
networks in the differentiation of CD4+ T cells and 
the plasticity between different T cell lineages, 
especially Th17 and Treg cells. A recent new 
strategy for identifying regulatory networks 
controlling Th17 cell differentiation and the 
plasticity have shown the existence of novel factors 
including the Mina, Fas, Pou2af1, Tsc22d3, and 
Fosl2 genes and dynamism among key 
transcriptional regulators (Ciofani et al., 2012; 
Yosef et al., 2013). 
3- Role of Th17 cells in 
inflammation 
It has been established that Th17 cells are critically 
involved in the pathogenesis of autoimmunity, gut 
inflammation, tissue inflammation and cancer, 
whereas Th17 cells contributes to protection against 
a variety of bacteria and fungi. Emerging data on 
Th17-mediated diseases suggest that different types 
of IL-17-producing T cells exist in vivo, which 
might be divided into pathogenic or non-pathogenic 
Th17 cells.  
Th17 cells produce IL-17 (IL-17A), IL-17F, IL-
17A/F heterodimers, IL-21, IL-22, and GM-CSF as 
well as other chemokines such as CXC cytokines 
(Korn et al., 2009). In an early study, IL-17A and 
IL-22 secreted from activated T cells were 
recognized as pro-inflammatory cytokines 
(Dumoutier et al., 2000a; Yao et al., 1995, Ouyang 
et al., 2008). Infante-Duarte et al. suggested that 
effector CD4+ T cells primed by B. burgdorferi 
highly produced IL-17 in inflammatory lesions, and 
such cell-types were distinct from Th1 and Th2 cell 
types (Infante-Duarte et al., 2000). Following this 
initial demonstration, Ye at al. reported that IL-17 
secreted from CD4+ T cells protected against 
Klebsiella pneumonia for host defense. 
Role of IL-22 in Th17 cells 
IL-22 as well as IL-17 plays a critical role in host 
defense and protecting against tissue damage. IL-22 
signaling is transmitted through a heterodimeric 
receptor complex composed of IL-10R2 and IL-
22R1 (Kotenko et al., 2001; Xie et al., 2000). IL-
22R is mainly expressed in epithelial tissues, 
including keratinocytes, hepatocytes, and intestinal 
and respiratory epithelial cells, but not in immune 
cells (Aggawal et al., 2001; Ouyang et al., 2008; 
Rutz et al., 2013). The biological functions of IL-22 
are known to be protective against infection and 
inflammation because IL-22 contributes to tissue 
maintenance, repair, and wound healing through the 
expression of anti-microbial, antiapototic proteins 
and proteins involved in cell proliferation via IL-
22R in intestinal epithelial cells and goblet cells 
(Rutz et al., 2013). 
IL-22 plays a protective role against bacterial 
infections. Neutralizing IL-22 secreted by the Th17 
lineage led to the failure to clear pathogen from 
infected lung by K. pneumonia, and in turn the 
early death of infected animals (Aujla et al., 2007). 
In this report, IL-17A produced from Th17 cells 
synergized with IL-22 to protect against bacteria. 
 
Figure 2. The plasticity between Th17 cells and Treg, and various types of Th17 cells expanded by IL-23. TGF-β1 is 
required for the initial Th17 differentiation in the presence of IL-6. The Th17 cells produce IL-17 and IL-10. TGF-β1 also induces 
iTreg. In general, the plasticity of Th17 and Treg cells is tightly regulated in normal condition. However, once an antigen induces 
inflammation, macrophages and dendritic cells produce IL-23. IL-23 can convert non-pathogenic Th17 cells into pathogenic 
ones. In contrast, IL-23 can inhibit the generation of Treg cells. IL-23-induced Th17 cells convert different cytokine- producing 
Th17 cells. IL-6 synergized with IL-1 and IL-23 emerges IL-22 and IFN-γ- producing Th17 cells. IL-6 alone is enough to induce 
IL-22-producing T cells. IL-23 alone also promoted IFN-γ-producing T cells. 
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The coexpression of both IL-17 and IL-22 in Th17 
cells are important for expression of antimicrobial 
peptides, as mentioned above.  
The expression pattern of IL-17 and IL-22 in CD4+ 
T cells, however, varies according to a cytokine 
milieu. IL-6 and/or IL-23 induced IL-22 expression 
in vitro in the absence of TGF-β (Qu et al., 2013). 
In contrast, TGF-β inhibited the expression of IL-22 
(Zheng Y et al., 2007), whereas TGF-β is essential 
for the differentiation of Th17 in the presence of IL-
6 (Figure 2). Moreover, IL-6 deficiency did not 
affect the frequency of IL-22 cell population in vivo 
(Zenewicz et al., 2008). These results suggest that 
IL-22 is produced by not only Th17 cells but also 
other immune cells. Therefore, not all Th17 cells 
might play a protective role for host defense 
through IL-22 production.  
Likewise, although IL-22 played a protective role in 
infection by various kinds of bacteria, including C. 
rodentium, M. tuberculosis, and Salmonera 
typhimurium, the sources of IL-22 was assumed to 
be not from Th17 cells (Zheng et al., 2008; Schulz 
et al., 2008; Dhiman et al., 2009). Moreover, NK 
cells as well as CD4+ T cells are involved in 
protection against IBD by IL-22, whereas IL-17A 
contributed to exacerbation of IBD (Zenewicz et al., 
2008). In contrast, IL-22 produced from effector 
Th17 cells contributed to promotion of CD-like 
experimental colitis (Yen et al., 2006; Strober et al., 
2007). In line with these reports, Ahern et al. has 
demonstrated that IL-23 promotes intestinal 
inflammation through directly enhancing the 
development of effector Th17 cells, which secret 
IL-17, IFN-γ and possibly IL-22 (Figure 2). 
Moreover, IL-22-expressing Th17 cells transferred 
into IL-22 deficient host mice provided protection 
against hepatitis, whereas IL-17 had no apparent 
role in liver inflammation (Zenewicz et al., 2007). 
However, Xu et al. and Nagata et al. have shown 
that IL-17 is required for the development of 
hepatitis. Although these reports appear to be 
contradictory, CD4+ T cells, which dominantly 
produce IL-22 rather than IL-17, might be 
protective against hepatitis, whereas IL-23-induced 
Th17 cells might have the pathogenicity in liver 
inflammation. In agreement with this, Zheng Y et 
al. has reported that the production of IL-17 and IL-
22 from Th17 cells is differentially controlled, and 
Th17 cells enhanced by IL-23, which produce IL-
22, are essential for dermal inflammation and 
acanthosis. 
IL-23/Th17 axis 
The IL-23/Th17 axis is clearly involved in various 
autoimmune diseases, including rheumatoid 
arthritis, multiple sclerosis, psoriasis, and IBD 
(Iwakura and Ishigame, 2006). IL-23 plays an 
important role in the maintenance and expansion of 
Th17 cells, and makes Th17 cells "pathogenic" 
(Figure1). As mentioned above, although different 
types of effector Th17 cells reside in inflammatory 
lesions (Figure 2), a growing number of reports 
have shown that IL-17 and IL-23 critically 
contribute to the pathogenesis of RA, in which IL-
17A and IL-17F play an important role in joint 
inflammation and bone erosion. Arthritis associated 
with psoriasis (psoriatic arthritis) is also dependent 
on Th17 cells activated by IL-23 (Maeda et al., 
2012).  
The elevation of IL-23 and IL-17 were detected in 
synovial fluid, synovial tissues and sera of RA 
patients but not of osteoarthritis (Alfadhli, 2013). 
IL-23 is also pivotal for the onset of EAE (Cua et 
al., 2003). IL-23 or IL-23R deficient mice were 
resistant to EAE (Awasthi et al., 2009). IL-17A and 
IL-17F double knockout mice showed critical 
reduction of the development of EAE, whereas the 
effect of IL-17F on EAE development is less than 
that of IL-17A in mice (Ishigame et al., 2007). 
More recently, Kang et al. has reported that IL-17 is 
involved in perturbation of the maturation of 
oligodendrocyte lineage cells, which might lead to 
inflammation and neurodegeneration in MS. 
Pathogenic Th17 cells produce GM-CSF (Figure 1), 
which is an important cytokine for induction of IL-
23 in dendritic cells (McGeachy et al., 2011). It has 
been reported that neutralizing GM-CSF at the 
effector stage results in suppression of the further 
development of EAE (El-Behi et al., 2011). Thus, 
GM-CSF is also required for the maintenance and 
expansion of Th17 cells possibly through the 
enhancement of IL-23. 
Th17 cells in host defense 
Th17 cells were increased at the mucosal sites after 
infection (Happel et al., 2005; Mangan et al., 2006). 
So far, it has been demonstrated that Th17 cells are 
involved in protection against a variety of bacteria 
such as Candida albicans, Staphylococcus aureus, 
Citrobacter rodentium, Salmonella and Bordetella 
pertusis (Peck and Mellins, 2010). However, the 
role of IL-17 and Th17 cells in protection against 
Asperillus fumigatus and other fungi are diverse 
and controversial (Muranski et al., 2013). One of 
the reasons is that the inflammatory milieu for the 
generation of Th17 cells is different in infection by 
different types of fungi, in which macrophages and 
dendritic cells recognize different kinds of fungal 
pattern recognition receptors (PRRs) such as 
Dectin-1, Dectin-2, Mincle and MR, and produce 
inflammatory cytokines for Th17 polarization, 
including IL-6, IL-1β, TNF-α and IL-23 as well as 
GM-CSF (Wüthrich et al., 2012). Zielinski et al. 
has reported that by eliciting different cytokines 
respectively, C. albicans and S. aureus prime 
different types of IL-17-producing T cells "Th17" 
cells that produce IFN-γ or IL-10 respectively, 
which might be significant for answering the 
question of what makes pathogenic or non-
pathogenic Th17 cells. 
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Th17 cells in cancer 
The role of Th17 cells in cancer displays 
complexity in various types of tumor immunity. 
Although it seems that the pathogenic role of IL-23-
induced Th17 cells has been consistently 
documented in autoimmunity, Th17 cells in cancer 
display both anti-tumorigenic and pro-tumorigenic 
functions (Zou and Restifo, 2010). Administration 
of IL-23 and IL-23-producing dendritic cells, has 
been reported to inhibit tumor growth (Kaiga et al., 
2007; Hu et al., 2006), whereas IL-23 has been 
shown to promote tumor incidence and growth 
(Langowski et al., 2006). The role of IL-17 in 
tumor immunity is also controversial, although the 
source of IL-17 is not only Th17 cells, but also 
other types of T cells, including CD8+ T cells 
(known as Tc17 cells) and Rorγt+ Foxp3+ T cells 
(Li and Boussiotis, 2013). IL-17 enhanced tumor 
growth through the promotion of tumor 
vasculization, especially in some immune-deficient 
mice (Zou and Restio, 2010). In contrast, in 
immunocompetent mice, IL-17 played a protective 
role against tumor growth (Benchetrit et al., 2002; 
Kryczek et al., 2009; Hirahata et al., 2001). 
Although Th17 cells are present in tumor 
microenvironment, the number of Th17 cells 
represents a minor population of effector T cells 
(Kryczek et al., 2007), suggesting that the 
frequency of Th17 cell population is tightly 
regulated in tumor immunity. The number of Treg 
and Th17 cells inversely correlates in the same 
tumor (Zou and Restifo, 2010). It has also been 
reported that, in the microenvironment of ulcerative 
coloitis (UC) and associated colon cancer, not only 
Th17 cells but also IL-17+Foxp3+ T cells are 
detected (Kryczek et al., 2011). Thus, the character 
of IL-17-producing CD4+ T cells might be 
classified more precisely in the context of tumor 
immunity. 
Balance between Th17 cells and Treg in 
autoimmunity 
It seems that there is no doubt that Treg cells play a 
critical suppressive role in immune responses in 
vitro and in vivo (Shevach et al., 2009; Vignali et 
al., 2008). Treg cells are a potent inducer of IL-10 
and TGF-β1, resulting in suppression of effector T 
cell functions. However, the balance between Th17 
and Treg cells in vivo is dependent on the context 
of inflammatory disease. The existence of Treg 
cells does not always suppress the function of Th17 
cells. Treg promoted Th17 cell development 
through IL-2 regulation rather than control of 
TGFβ1 (Pandiyan et al., 2011; Chen et al., 2011). 
IL-2 is a critical cytokine in deciding a dichotomy 
between Th17 and Treg cells. Treg cells induced by 
IL-2 combined with TGF-β or all-trans retinoic 
acid, were resistant to Th17 cells (Muchida et al., 
2007; Zheng et al., 2008; Zhou et al., 2010). 
Conversely, IL-6 is a strong inducer of Th17 cells 
differentiation. Zheng has indicated that IL-6 can 
convert nTregs into Th17 cells, and other CD4+ T 
cells (Zheng, 2013). It is notable that IL-6 plays a 
critical role in conversion of Foxp3+ CD4+ T cells 
into pathogenic Th17 cells in autoimmune arthritis 
(Komatsu et al., 2014). Th17 cell expansion is also 
regulated by TGFβ1 secreted from Th17 cells itself 
but not Treg cells (Gutcher et al., 2011). Rather, it 
seems that high concentration of TGF-β reduces 
Th17 cell populations (Zhou et al., 2008).  
The concentration of TGF-β1 is one of the 
important factors, which drives or inhibits the 
differentiation of Th17 cells (Zhou et al., 2008). 
High levels of TGF-β1 inhibited Th17 cell 
differentiation and enhanced the development of 
iTreg through high expression of Foxp3. In such a 
cytokine milieu, Foxp3 induced by TGF-β 
interacted with Rorγt, and in turn antagonized the 
function of Rorγt in CD4+ T cells, in which the 
expression of IL-23R, IL-22 and IL-17 was 
repressed (Zhou and Littmann, 2009). In contrast, at 
low concentrations, TGF-β1 was helpful for the 
generation of Th17 cells in synergy with IL-6 or IL-
21 (Zhou et al., 2008), although it is still not clear 
how IL-6 or IL-21 overcomes the inhibitory effect 
of Foxp3 on Rorγt function. Runx-1 controls the 
differentiation of Th17 cells thorough binding both 
Foxp3 and Rorγt (Zhang et al., 2008). The 
interaction of Runx-1 with Rorγt promoted the 
transcription of the IL-17 gene, whereas Foxp3 
inhibited Rorγt- and Runx-1-induced IL-17 
expression by binding to Runx-1 (Zhang et al., 
2008), suggesting that the role of Runx-1 is also 
dependent on the concentration of TGF-β1. 
4- Therapy (treatment of Th17-
dependent autoimmunity) 
A great number of recent studies have revealed that 
the biology of Th17 cells in mice is broadly 
common with phenomena in humans (Tesmer et al., 
2008; Jong et al., 2010). Th17 cells in humans play 
an important role in the pathogenesis of rheumatoid 
arthritis, psoriasis, asthma, inflammatory bowel 
disease (IBD) and transplantation rejection. 
Accordingly, blocking pro-inflammatory cytokines, 
including IL-6, IL-1β, IL-23, and IL-17 as well as 
GM-CSF, will lead to the abatement of tissue 
inflammation, gut inflammation and autoimmunity. 
Several anti-IL-17A monoclonal antibodies, 
including secukinumab and ixekizumab, and anti-
IL-17A receptor monoclonal antibody, brodalumab 
have been treated to patients in the process of phase 
II clinical trials (Kellner et al., 2013). Secukinumab 
is most likely to be clinically efficacious in RA. An 
anti-IL-1β monoclonal antibody, gevokizumab is 
currently being investigated in a Phase â…¡ clinical 
program. An anti-IL-12/IL-23 monoclonal 
antibody, usutekinumab has been demonstrated the 
high efficacy in the treatment of patients with 
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psoriasis (Krueger et al., 2007). An anti-GM-CSF 
monoclonal antibody, mavrilimumab for treatment 
of rheumatoid arthritis has shown promising results 
under phase II clinical trial (Burmester et al., 2013). 
In the future, emerging data will establish the 
efficacy of these monoclonal antibodies against 
several autoimmune diseases such as rheumatoid 
arthritis.  
IL-6 is involved in the initial differentiation of 
Th17 cells (Betteli et al., 2006). In mice, blockade 
of IL-6 pathway has been shown to result in a 
decrease of the frequency of Th17 cell population 
(Nowell et al., 2009; Serada et al., 2009). A 
humanized anti-IL-6 receptor antibody 
(Tocilizumab, TCZ) displayed a remarkable 
protective effect in patients with rheumatoid 
arthritis as well as Castleman's disease and juvenile 
idiopathic arthritis (Genovese et al., 2008; Tanaka 
et al., 2012). Although the biological effect of TCZ 
on human autoimmune disease is complex (Tanaka 
et al., 2013), Samon et al. have demonstrated TCZ 
affects the IL-6/Th17 axis in patients with 
rheumatoid arthritis, in which the ratio of Th17 
cells to Treg cells was significantly reduced. 
Therefore, administration of IL-6 blockade (TCZ) 
might be highly efficacious against not only such 
diseases as mentioned above, but also Th17 cell-
dependent diseases, including IBD and psoriasis, 
and cancer.  
On the contrary, although elevation of IL-6 level in 
inflammatory lesions leads to the exacerbation of 
autoimmunity, it remains to be understood why IL-
6 is overproduced in autoimmune disease such as 
rheumatoid arthritis. A recent report has shown that 
posttranscriptional regulation of IL-6 production is 
essential for immune homeostasis. Zc3h12a (known 
as Regnase-1, MCPIP) constitutively degrades level 
of IL-6 mRNA trough binding to its 3'UTR, 
whereas Zc3h12a deficiency led to spontaneous 
autoimmunity (Matsushita et al., 2009). Moreover, 
our recent study has shown that Arid5a controls IL-
6 level in vivo through stabilization of IL-6 mRNA. 
Arid5a deficient mice are resistant to EAE, in 
which the frequency of Th17 cell population is 
dramatically reduced (Masuda et al, 2013, PNAS). 
Notably, Arid5a counteracted the destabilization 
effect of Zc3h12a (Masuda et al., 2013). 
Consequently, imbalance between Arid5a and 
Zc3h12a in vivo might be involved in 
autoimmunity. Given that administration of TCZ is 
efficacious against several autoimmune diseases, 
the monoclonal antibody targeting Arid5a might be 
also clinically useful. 
Concluding remarks 
Since IL-17-producing CD4+ T cells have been 
shown to be involved in various types of 
inflammatory diseases, our understanding of the 
pathogenesis of such diseases as rheumatoid 
arthritis, multiple sclerosis, and psoriasis, has been 
dramatically improved since the original concept of 
a Th1/Th2 paradigm. However, emerging data on 
Th17 cells have revealed that IL-17-producing 
CD4+ T cells are not simple cell population. Th17 
cells are classified into pathogenic or non-
pathogenic ones. IL-23 is a critical factor, which 
enhances the pathogenecity of Th17 cells. Recent 
data suggests that TGF-β3 and sodium chloride as 
well as IL-23 are involved in the generation of 
pathogenic Th17 cells. In contrast, TGFβ1 secreted 
from Treg cells inhibits the conversion into 
pathogenic Th17 cells by attenuating IL-23 
production from activated macrophages and 
dendritic cells, whereas TGF-β1 is essential for the 
initial induction of Th17 cells. Moreover, the 
concentration of TGFβ1 is essential for the 
plasticity of Th17 and Treg cells. Taken together, 
Th17 cells play a pathogenic or protective role in 
infection and inflammatory disease in an antigen-
dependent manner. Consequently, to identify which 
molecules and signaling pathways are critical for 
the generation of pathogenic Th17 cells, will lead to 
the development of more efficacious therapeutic 
drugs for Th17 cell-dependent inflammatory 
disease. 
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